Skip to main content
EDIT logo

EDIT · Editas Medicine, Inc.

Track EDIT — free
$1.70 -0.01 (-0.58%)
Market Cap
$263.92M
Shares
154.34M
Volume · Nov 19 1.93M Avg daily vol (3M) 2.65M

Price & Indicators

 

Key stats

Close
$1.71
Open
$1.80
Day range
$1.70–1.83
52-week closing range
$1.67–3.75
Average volume, 30 days
2.2M
Short interest
38.7M · 25.1% of shares · 17.6 days
Short volume, last session
65%
Last earnings
Nov 9, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2020 to Nov 2026

Up next

Mar 8, 2027 Est · unconfirmed · in 15 wks
call held Aug 7, 2024

Latest documents

2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
EDIT-401 trial approved in Australia as net loss narrowed

Editas Medicine received approval in October 2026 to initiate the Strive trial of EDIT-401 in Australia, with dosing on track for 2026. Net loss was $66.6 million for the nine months ended September 30, 2026, versus $154.4 million in 2025.

Revenue $10.37M ▲ 37.4% Net loss $23.39M Diluted EPS -$0.15
Read from the MD&A section
3 source passages
In October 2026, we announced that we had received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia (“HeFH”) in Australia. We are on track to begin patient dosing in 2026 and report initial safety and tolerability data in the first quarter of 2027. Our net losses were $66.6 million and $154.4 million for the nine months ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 9
Current report 8-K
EDIT-401 earns Australia trial approval, cash runway reaches 2028

Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028.

Financial results
3 source passages
Editas received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) to initiate the Phase 1/2 Strive study of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia. The Company remains on track to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027. Cash, cash equivalents, and marketable securities as of September 30, 2026, were $190.2 million compared to $146.6 million as of December 31, 2025. The Company expects that its existing cash, cash equivalents, and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements into the second half of 2028. Open the document at this passage
Oct 8
Current report 8-K
Regulation FD disclosure, Other events

Editas Medicine, Inc. received approval to initiate the Phase 1/2 Strive™ trial of EDIT-401 in Australia; New Zealand review is pending, and initial safety and tolerability data are expected in the first quarter of 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$49.83M
Trailing 12 months
Net income (TTM)
−$72.22M
Trailing 12 months
Revenue growth YoY
+37.4%
Year over year
Operating margin
-151.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-41.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$133.38M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+70.5%
Year over year · more shares
Price change (1Y)
-32.1%
Trailing year
Short interest
25.1%
Latest settlement · 17.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −37%
below
Price vs 50-day avg −33%
below
RSI (14) 30
oversold
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −31%
trailing
6-month return −49%
trailing
YTD return −17%
this year
Relative strength −43%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
25.09% of shares out · ▲ +1.4% MoM · 17.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
224 holders — mid 3-yr range
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth +133%
Y/Y
EPS growth +38%
Y/Y
Free cash flow $-165.8M
Balance sheet $88.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −54%
past year
ATR 12.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−37% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
30 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
25.09% of shares out · ▲ +1.4% MoM · 17.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
224 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 2% Range high $4
vs 200-day avg -37% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EDIT
Editas Medicine, Inc.
this stock
$263.92M -16.6% +132.6% — 25.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
224
% held
90.4%
Net QoQ
+20.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
152
View
Short & Settlement
Short Interest Rising
Shares short
38.7M
Days to cover
17.6d
Change
+535.3K sh
View
Short Volume
Short vol %
65%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
446
Value
$1.0K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
48.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Apr 10, 2023
View
Financials
Financials
Revenue (FY)
$40.5M
Net income (FY)
$-160.1M
EPS diluted
$-1.80
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
22

Editas Medicine received HREC approval and completed TGA notification for the Phase 1/2 Strive study of EDIT-401 in Australia, with dosing planned this year. Cash and marketable securities totaled $190.2 million, supporting a runway into the second half of 2028.

View
Proposed Sales
Value
$2.3K
Shares
700
Filed
Aug 31, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Editas Medicine Announces Third Q…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
EDIT -20.1% -31.3% -48.8% -36.0% -16.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -14.6% -25.0% -43.2% -30.7% -21.6%
Key facts CIK 1650664 CUSIP 28106W103 13F (30d) 243 filings 207 filers Visit website Investor relations